CNS
-
Read FlipbookThe BNSS Scale In Translation: A Review of Psychometric Properties and Beyond
-
Read FlipbookQuality First: Using Data to Inform Site Selection in CNS
WCG MedAvante-ProPhase espouses a rather simple philosophy: minimize variability, generate cleaner data.
-
Read FlipbookThe Power to Pivot: Decoding CNS Trials with Data Analytics
In this interview, Jesse Kooker, MPH, VP of Clinical Data Sciences at WCG's MedAvante-ProPhase, looks at the clinical development industry through the lens of data analytics.
-
Read FlipbookQ&A with CNS Expert, Dr. Andrew Cutler
Dr. Cutler, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Read PostCNS Science Has Outpaced Tool Development; It’s Time to Catch Up
For the first time in decades, we’re developing CNS drugs with new mechanisms of action. Unfortunately, our measurement tools are stuck in the past.
-
Read FlipbookThe 4 Data-Driven Archetypes
Biopharmaceutical organizations recognize the extraordinary power of data but vary significantly in how they put it to use, particularly in the world of CNS trials.
-
25:31Watch VideoInterview with Dr. Andrew Cutler
Dr. Cutler shares his insights on the current challenges and opportunities for CNS therapies and clinical trials during an energizing conversation with Dr. Mark Opler.
-
Read FlipbookQ&A with CNS Expert, Dr. Philip Scheltens
Philip Scheltens, MD, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Christopher Randolph, PhD, ABPP-CN, chief scientific officer...
-
Read FlipbookQ&A with Dr. Sofija Jovic
Increasingly, sponsors are turning to experts who have “been there, done that” to help them develop protocols for their CNS trials. In this wide-ranging interview, Sofija Jovic, PhD, MBA, of WCG...
-
Read FlipbookQ&A with CNS Expert, Dr. Leo Verhagen Metman
Leo Verhagen Metman, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation...
-
Read FlipbookAddressing Suggestibility as a Psychological Phenomenon in Clinical Trials
It is important to understand patient perspectives and to anticipate how subjects in research studies may be impacted by the presence of digital tools, devices, and mobile health applications
-
Read Flipbook
Improving Subject Selection and Endpoint Management in Alzheimer's Trials
-
Read FlipbookQ&A with CNS Expert, Dr. Michael Liebowitz
Dr. Michael Liebowitz, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...
-
Read Flipbook
Genetic Counselors at the Forefront of Helping Researchers Brace for the "Silver Tsunami" of CNS Disorders
An aging population is triggering a “silver tsunami” of neurodegenerative diseases like Alzheimer’s and Parkinson. At the same time, precision medicine holds great promise for many CNS disorders.
-
Read FlipbookThe brief negative symptom scale (BNSS): Sensitivity to treatment effects
-
Read FlipbookQ&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Read Flipbook
2018 Tufts CSDD IMPACT Report for CNS
This report summarizes a recent Tufts CSDD analysis of 509 drugs and biologics that received FDA approval from 2000 to 2017.
-
Read FlipbookQ&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Read FlipbookWCG MedAvante-ProPhase Adds Prominent Thought Leaders to its CNS Scientific Leadership Team
The WCG Clinical Services Division has added eight internationally recognized thought leaders to its Scientific Leadership Team.
-
Read FlipbookeCOA: Keep it Simple, Exec Argues
Nearly half of all clinical trials still use paper as the primary - or even sole - source of records while barely a quarter of trials use eCOA or ePRO
-
Loading More...
